BIONDVAX PHARMA/S (NASDAQ:BVXV) was upgraded by equities research analysts at ValuEngine from a “hold” rating to a “buy” rating in a note issued to investors on Thursday, September 5th, ValuEngine reports.
BIONDVAX PHARMA/S stock traded up $0.20 during trading hours on Thursday, hitting $5.72. The stock had a trading volume of 2 shares, compared to its average volume of 7,918. The stock has a market capitalization of $36.95 million, a price-to-earnings ratio of -1.59 and a beta of 1.17. BIONDVAX PHARMA/S has a 1-year low of $3.51 and a 1-year high of $7.26. The stock’s fifty day moving average is $5.96 and its two-hundred day moving average is $6.01.
BIONDVAX PHARMA/S Company Profile
BiondVax Pharmaceuticals Ltd., a clinical stage biopharmaceutical company, focuses on developing and commercializing immunomodulation therapies for infectious diseases primarily in Israel. Its product candidate is M-001, a synthetic peptide-based protein, which has completed Phase II clinical trials that is used for treating seasonal and pandemic strains of the influenza virus.
Recommended Story: Benefits of owning preferred stock
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for BIONDVAX PHARMA/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIONDVAX PHARMA/S and related companies with MarketBeat.com's FREE daily email newsletter.